Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181610 · ClinicalTrials.gov registry record · Phase 2
Recombinant Human Prolactin for Lactation Induction
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00181610: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00181610 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181610, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).
Interventions
- BIOLOGICAL Normal Saline
- DRUG Recombinant Human Prolactin
- BIOLOGICAL Recombinant human prolactin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181610
The ClinicalTrials.gov registry entry for NCT00181610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Normal Saline is the first listed.
NCT00181610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181610 about?
NCT00181610 is a clinical study titled "Recombinant Human Prolactin for Lactation Induction". The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).
What is the current status of trial NCT00181610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2004-09. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00181610?
The interventions under investigation include: Normal Saline (BIOLOGICAL), Recombinant Human Prolactin (DRUG), Recombinant human prolactin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00181610?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.